Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China-Prevalent Form of NSCLC Responds to AstraZeneca Drug

publication date: Dec 6, 2016
AstraZeneca announced positive results from a Phase III trial of Tagrisso in patients with relapsed non-small cell lung cancer. Tagrisso is a third-gen oral epidermal growth factor receptor (EGFR) inhibitor that targets NSCLC with the T790M mutation. Although only 10%-15% of NSCLC patients in the west have the mutation, about 50% of cases in China and east Asia do. In the trial, Tagrisso raised the median time-to-progression to 10.1 months from 4.4 months. Tagrisso, which is available in the US as a second-line treatment, is under Fast-Track review in China. More details....

Stock Symbol: (NYSE: AZN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here